Last checked at 
(Alliance News) - IP Group PLC on Wednesday reported that its majority-owned portfolio company, Istesso Ltd, has begun a phase 2b trial of its lead drug, MBS2320, in rheumatoid arthritis.
MBS2320 is an investigational drug which reduces inflammation and helps the remodelling of damaged tissue. IP Group explained that this dual mode-of-action enables the drug to offer the potential to reverse underlying pathology in bone and joints.
The trial is investigating the efficacy and safety of multiple doses of MBS2320 in patients with rheumatoid arthritis who have had an inadequate response to methotrexate, another immunosuppressant used to treat the condition.
Istesso said it expects results from the study in 2024.
IP Group is an Oxford, England-based intellectual property commercialisation company. It holds a 56% stake in Istesso, an immunometabolism drug discovery and development firm.
Shares in IP Group were down 0.7% at 69.56 pence in London on Wednesday morning.
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
